Amarin Corp Plc (AMRN)

[lettruthringout]

Spain starts working Therapeutic Positioning Report for Vazkepa

This document provides a summary of the topics discussed at the meeting of the REvalMed SNS Coordinating Group (GC), on February 4, held by teleconference.

At the meeting it was agreed to start working on the Therapeutic Positioning Reports (IPT) of the following medicines with a positive opinion from the CHMP at the January 2021 meeting:

Vazkepa® (icosapent ethyl): from Amarin Pharmaceuticals Ireland Limited, indicated for the reduction of the risk of cardiovascular events in adults taking statins, with a high risk of cardiovascular events, high triglycerides (> 150 mg / dL) and

- established CV disease
- diabetes and one other CV risk factor

https://www.aemps.gob.es/informa/informes-de-posicionamiento-terapeutico/reuniones-gc-revalmed-sns/2021-7/informacion-de-la-reunion-del-gc-de-la-revalmed-sns-celebrada-el-4-de-febrero-de-2021/